Abstract: Acute coronary syndrome (ACS) is a severe disease which threatens human health. Dual antiplatelet is the cornerstone of the treatment of ACS. Clopidogrel, as a classical antiplatelet drug, has showed several flaws. However,Ticagrelor, a new antithrombtic drug, overcomes those deficiencies thanks to its special pharmacokinetic and pharmacodynamics characteristics. Many large clinical studies have confirmed the advantages of Ticagrelor in treatment of ACS patients with acute coronary syndrome as it greatly reduces the major cardiac events in ACS patients. New studies have provided a large number of evidence-based medical evidence and this paper is to review the pharmacological characteristics, current clinical studies and corresponding guidelines of Ticagrelor.